Circulating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer

MicroRNA-21 was upexpressed in gastric cancer (GC) indicating that it is a potential diagnostic biomarker for GC. In this study, 50 GC patients and 50 healthy controls were recruited. miR-21 levels in serum and peripheral blood mononuclear cells (PBMCs) were quantified using quantitative real-time P...

Full description

Saved in:
Bibliographic Details
Published in:Disease markers 2015-01, Vol.2015 (2015), p.1-8
Main Authors: Wang, Jianjun, Chen, Rui, Yao, Yongliang, Wang, Zeyou, Li, Guangxin, Wu, Jianhong, Pu, XiongYong
Format: Article
Language:English
Subjects:
Adult
Aged
Antigens, Tumor-Associated, Carbohydrate - metabolism
Biological markers
Biomarkers, Tumor - blood
Carcinoembryonic Antigen - metabolism
Development and progression
Female
Gene expression
Genetic aspects
Health aspects
Humans
Identification and classification
Male
MicroRNA
MicroRNAs - blood
Middle Aged
Properties
Stomach cancer
Stomach Neoplasms - blood
Stomach Neoplasms - genetics
Stomach Neoplasms - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MicroRNA-21 was upexpressed in gastric cancer (GC) indicating that it is a potential diagnostic biomarker for GC. In this study, 50 GC patients and 50 healthy controls were recruited. miR-21 levels in serum and peripheral blood mononuclear cells (PBMCs) were quantified using quantitative real-time PCR. CA199, and CEA were measured using electrochemiluminescence assay. The sensitivity and specificity of circulating miR-21, CA199 and CEA in GC diagnosis, the correlation of circulating miR-21 to clinicopathological features, and the diagnostic value of miR-21 in different GC stages were determined. The levels of miR-21 in both serum and PBMCs increased significantly in GC patients comparing to healthy controls; however, no correlation was observed between circulating miR-21 level and clinicopathological features. The sensitivity and specificity of miR-21 in serum and PBMCs, and CA199 and CEA in GC diagnosis were 88.4%, 79.6%, 81.3%, 73.4%, 60.5%, 55.9%, and 68.6%, 59.3%, respectively. The positive prediction rates of circulating miR-21 in GC stages I to IV were all around 90%, while those of CA199 and CEA were around or less than 50%. Our data suggest circulating miR-21 (both in serum and in PBMCs) can serve as a good biomarker for GC and could be used in diagnosis of early (stage I) and late GC (stage IV).
ISSN:0278-0240
1875-8630
DOI:10.1155/2015/435656